Combination focus: Much of its regulatory development is tied to dual-therapy use with GLP-1 drugs, positioning it as a combination obesity therapy rather than a standalone peptide
In many cases, definitive treatment of gallbladder disease allows patients to safely continue their GLP-1 medication if clinically indicated
While certain synthetic compounds, such as benfotiamine and TUDCA, can be beneficial, many nutrients are best obtained from naturally sourced supplements
Injections are clearly superior when absorption is impaired, such as in pernicious anemia or after gastrointestinal surgery
Methylene chloride: A two-year inhalation toxicity and oncogenicity study in rats and hamsters*1
Foundayo (orforglipron), the newer oral small-molecule GLP-1, has no food or water restrictions